Literature DB >> 23124277

A missense polymorphism (rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population.

Su Kang Kim1, Hae Jeong Park, Il Ki Hong, Joo-Ho Chung, Young Gyu Eun.   

Abstract

Toll-like receptors (TLRs) are important components of innate immune response. The aim of this study was to investigate whether TLR gene cluster (TLR10-TLR1-TLR6) polymorphisms are associated with the etiology of papillary thyroid carcinoma (PTC) and its clinicopathologic characteristics. We recruited 94 PTC patients and 325 control subjects. Genotypes for each SNP were determined by direct sequencing. SNPStats and SPSS 18.0 were used to evaluate odds ratios (ORs), 95 % confidence intervals (CIs), and P values. Multiple logistic regression analyzes of genetic data were performed. The missense SNP rs11466653 was associated with small tumor size (<1 cm) in PTC. The frequency of the rs11466653 T allele was higher in PTC patients with tumors <1 cm in size than in the control group (95.8 vs. 87.2 %; P = 0.021, OR = 0.30, 95 % CI = 0.11-0.83). The T allele of rs11466653 (T/C, Met326Thr) in TLR10 may be a risk factor for the development of tumors in PTC in the Korean population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124277     DOI: 10.1007/s12020-012-9783-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  27 in total

1.  Three novel mammalian toll-like receptors: gene structure, expression, and evolution.

Authors:  X Du; A Poltorak; Y Wei; B Beutler
Journal:  Eur Cytokine Netw       Date:  2000-09       Impact factor: 2.737

Review 2.  Role of Toll-like receptors in pathogen recognition.

Authors:  S Janssens; R Beyaert
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

3.  Discrimination of bacterial lipoproteins by Toll-like receptor 6.

Authors:  O Takeuchi; T Kawai; P F Mühlradt; M Morr; J D Radolf; A Zychlinsky; K Takeda; S Akira
Journal:  Int Immunol       Date:  2001-07       Impact factor: 4.823

4.  Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88.

Authors:  Uzma Hasan; Claire Chaffois; Claude Gaillard; Virginie Saulnier; Estelle Merck; Sandra Tancredi; Chantal Guiet; Francine Brière; Jaromir Vlach; Serge Lebecque; Giorgio Trinchieri; Elizabeth E M Bates
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

5.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.

Authors:  R Medzhitov; P Preston-Hurlburt; C A Janeway
Journal:  Nature       Date:  1997-07-24       Impact factor: 49.962

Review 6.  The role of Toll-like receptors and adaptive immunity in the development of protective or pathological immune response triggered by the Trypanosoma cruzi protozoan.

Authors:  Andrea Pellegrini; Natalia Guiñazu; Laura Giordanengo; Roxana Carolina Cano; Susana Gea
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

7.  Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells.

Authors:  T Chuang; R J Ulevitch
Journal:  Biochim Biophys Acta       Date:  2001-03-19

8.  Polymorphisms in Toll-like receptor genes--implications for prostate cancer development.

Authors:  Zeljko Vidas
Journal:  Coll Antropol       Date:  2010-06

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk.

Authors:  Victoria L Stevens; Ann W Hsing; Jeffrey T Talbot; Siqun Lilly Zheng; Jielin Sun; Jinbo Chen; Michael J Thun; Jianfeng Xu; Eugenia E Calle; Carmen Rodriguez
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

View more
  8 in total

1.  Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.

Authors:  Yang-Jing Chen; Rui-Min Zhao; Qian Zhao; Bai-Ya Li; Qing-Yong Ma; Xiao Li; Xia Chen
Journal:  Tumour Biol       Date:  2016-01-07

2.  TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider?

Authors:  Myriem Boufraqech; Catsim Fassassi; Electron Kebebew
Journal:  Endocrine       Date:  2012-11-09       Impact factor: 3.633

Review 3.  Relevance of single-nucleotide polymorphisms in human TLR genes to infectious and inflammatory diseases and cancer.

Authors:  A Trejo-de la O; P Hernández-Sancén; C Maldonado-Bernal
Journal:  Genes Immun       Date:  2014-03-13       Impact factor: 2.676

4.  Association of IRAK1 Gene Polymorphism rs3027898 With Papillary Cancer Restricted to the Thyroid Gland: A Pilot Study.

Authors:  Anthoula Chatzikyriakidou; Angeliki Chorti; Theodosios Papavramidis
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

5.  Association of TLR6 single nucleotide polymorphisms and clinical features of ischemic stroke in Korean population.

Authors:  Seung-Ae Yang
Journal:  J Exerc Rehabil       Date:  2013-12-31

6.  Association of BID SNPs (rs8190315 and rs2072392) and clinical features of benign prostate hyperplasia in Korean population.

Authors:  Hosik Seok; Su Kang Kim; Koo Han Yoo; Byung-Cheol Lee; Young Ock Kim; Joo-Ho Chung
Journal:  J Exerc Rehabil       Date:  2014-12-31

Review 7.  Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells.

Authors:  Sabine Hombach-Klonisch; Suchitra Natarajan; Thatchawan Thanasupawat; Manoj Medapati; Alok Pathak; Saeid Ghavami; Thomas Klonisch
Journal:  Front Endocrinol (Lausanne)       Date:  2014-03-25       Impact factor: 5.555

8.  Toll-like receptor 10-1-6 gene cluster polymorphisms are not associated with benign prostatic hyperplasia in korean population.

Authors:  Su Kang Kim; Young Ock Kim; Byung-Cheol Lee; Koo Han Yoo; Joo-Ho Chung
Journal:  Int Neurourol J       Date:  2014-03-31       Impact factor: 2.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.